They could do so at a significant discount because vials are cheaper to produce than the branded injectables, making them a popular option for cash-paying patients
Daniel D'Agostino a a
Meet the Expert Rocio Salas-Whalen, M.D
On the other hand, Ozempic was approved in 2025 to help protect kidney health in people with type 2 diabetes and chronic kidney disease
In people with obesity and type 2 diabetes, a 2023 New England Journal of Medicine trial found that once weekly tirzepatide led to substantial and clinically meaningful weight reductions with a safety profile similar to other incretin based therapies
1,11,19 Novel pharmacological agents, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and ion channel blockers, have shown promising neuroprotective and pain management effects